IDH2 and central nervous system cancer: Genetic, DNA methylation, gene expression features have been demonstrated to influence the prognosis of glioma patients [1, 2], and related molecular signatures, such as isocitrate dehydrogenase genes 1 and 2 (IDH1/IDH2) status, O6-methylguanine-DNA methyltransferase (MGMT) promotor status, codeletion of chromosome arm 1p and 19q (1p/19q codel) and TERT promoter status have been applied widely in prognosis prediction [3].